FDA data Registry peer set 1 peer FDA shortage listed

Alternatives to allopurinol

FDA shortage status is active for allopurinol; 1 same-class SPL records are listed below for registry comparison only.

Brand: Zyloprim

Xanthine Oxidase Inhibitor Prescription 1 alternative found

allopurinol class peers while FDA lists an active shortage

allopurinol (Zyloprim) is on an FDA shortage listing while 1 other Xanthine Oxidase Inhibitor SPL records remain in this registry peer set (class inventory 2). Labeled indication field for allopurinol: This medicine is used to manage gout in adults.

Top FAERS reaction fields for allopurinol total 66,610 reports across 10 reactions, set beside febuxostat. Counts are exposure-weighted submissions, not per-patient risk.

About allopurinol

Allopurinol is a medicine that lowers uric acid levels in your body. It helps prevent gout attacks and other problems caused by high uric acid.

Used for: This medicine is used to manage gout in adults. Gout causes painful attacks, joint damage, and kidney problems. Allopurinol is also used in adults and children with leukemia, lymphoma, and solid tumors who are getting cancer treatment. It helps manage high uric acid caused by the cancer treatment. It can also help adults who get calcium oxalate kidney stones often.

1 Xanthine Oxidase Inhibitor peers (wide set)

Compare allopurinol vs febuxostat side-by-side →

allopurinol vs febuxostat · FAERS reaction fields

FAERS top-reaction field "Diarrhoea" shows the widest count spread between allopurinol and febuxostat in this extract (7,574-report gap on that field). Counts are exposure-weighted submissions, not prevalence rates.

Side Effect allopurinol febuxostat
Diarrhoea 8,423 849
Fatigue 7,965 598
Dyspnoea 7,658 620
Nausea 7,063 841
Death 6,665 515
Acute Kidney Injury 6,554 837
Pyrexia 5,943 526
Pneumonia 5,568 532

"-" means no reports for that reaction. Report counts reflect total FAERS submissions, not prevalence rates.

allopurinol shortage vs Xanthine Oxidase Inhibitor peer index

Shortage status

FDA shortage listing is active for allopurinol (status: To Be Discontinued). Peer rows remain a registry index, not a switch guide.

Frequently Asked Questions

Does FDA list a shortage for allopurinol while peers remain indexed?
Yes - allopurinol matched an active FDA shortage listing (To Be Discontinued) while 1 other Xanthine Oxidase Inhibitor SPL records remain in this peer index for field comparison only.

Registry note: Shortage listings and peer indexes are for registry orientation only. This information is for educational purposes only and is not a substitute for professional medical advice. Do not stop or change your medication without talking to your doctor or pharmacist.

Full allopurinol profile →

Field note for allopurinol: see also the generic vs brand label guide when reading Zyloprim SPL strings.